American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Classical pathway of complement activation in ITP: Inhibition by TNT003, a novel C1s inhibitor
    Meeting Abstract

    Peerschke, E. I. B.; Panicker, S.; Sughroue, A. M.; Bussel, J. B.
    Blood (2014)

    Fulltext@MSK | Save
  • A phase I open-label, multi-dose escalation study of the dual Syk/Jak inhibitor PRT062070 (cerdulatinib) in patients with relapsed/refractory B cell malignancies
    Meeting Abstract

    Patel, M.; Hamlin, P.; Strickland, D. K.; Pandey, A.; Coffey, G.; Leeds, J. M.; Levy, G. G.; Curnutte, J. T.; Wagner-Johnston, N.; Flinn, I. W.
    Blood (2014)

    Fulltext@MSK | Save
  • Msi2 maintains the MLL leukemia stem cell regulatory program
    Meeting Abstract

    Park, S. M.; Gonen, M.; Vu, L. P.; Minuesa, G.; Tivnan, P.; Barlowe, T.; Taggart, J.; Lu, Y. H.; Deering, R. P.; Hacohen, N.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Vemurafenib has potent antitumor activity in patients with relapsed/refractory BRAF mutant hairy cell leukemia
    Meeting Abstract

    Park, J. H.; Chung, S. S.; Chung, Y. R.; Won, H.; Kim, E.; Saven, A.; Wadleigh, M.; Stone, R. M.; Barrientos, J. C.; Rai, K. R.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Impact of the intestinal microbiota on infections and survival following hematopoietic stem cell transplantation
    Meeting Abstract

    Pamer, E. G.; Taur, Y.; Jenq, R.; van den Brink, M. R. M.
    Blood (2014)

    Fulltext@MSK | Save
  • An international data set for the study of chronic myelomonocytic leukemia (CMML) validates modern prognostic scoring systems and demonstrates a critical need for novel prognostication strategies
    Meeting Abstract

    Padron, E.; Garcia-Manero, G.; Patnaik, M. M.; Itzykson, R.; Lasho, T.; Nazha, A.; Rampal, R. K.; Sanchez, M. E.; Jabbour, E.; Al Ali, N. H.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Dose-adjusted EPOCH plus /- rituximab in older patients with high grade diffuse large B-cell lymphoma, Burkitt and T-cell lymphoma: An effective regimen with acceptable toxicity profile
    Meeting Abstract

    Owens, C. N.; Migliacci, J. C.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Younes, A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
    Meeting Abstract

    Oki, Y.; Fanale, M. A.; Romaguera, J. E.; Fayad, L.; Fowler, N.; Copeland, A. R. M.; Samaniego, F.; Kwak, L. W.; Neelapu, S. S.; Wang, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma
    Meeting Abstract

    Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save